Market News
Smart Trading. Simplified.
A Rare Opportunity to Turn $1,000 into $461,800
On August 30, 2019, a small firm won a contract from the Pentagon to build a strange new weapon. The Joint Chiefs of Staff calls this new weapon "Unstoppable." This under-the-radar company is not yet a household name.
Our research proves that anyone who gets in now could turn $1,000 into $461,800 >>>
Sponsored
Is Teradyne Stock A Buy?
Teradyne’s future prospects look bright as technology and semiconductors as a whole become more critical to applications. The advanced test solutions company, with attractive valuation, strong fundamentals and a high ROE, is set to benefit from an increasingly complex world. Teradyne, Inc. [NASDAQ: TER] is an American automatic test equipment (ATE) designer and manufacturer that […]
"The Biggest Drug Ever"
On August 23, 2018, a small biotech won a patent for a treatment that could help as many as 50 million people and save the U.S. as much as $20 TRILLION. Jim Cramer says a drug like this would be "The Biggest Drug Ever."
Our research shows that anyone who gets in today could turn every $1,000 into $1.1 million >>>
Sponsored
Is HCA Stock a Good Investment?
HCA Healthcare Inc (NYSE:HCA) is a Nashville, Tennessee-based healthcare company and component of the S&P 500. This means you’re likely already invested in it through a retirement fund and should understand more about it. The company owns and operates over 186 hospitals and thousands of care sites across the United States and United Kingdom. […]
"Tesla Killer" Stock Set to Skyrocket 1,000 Times Over
My friends complain all the time about charging their Teslas. It takes hours. Imagine their surprise when I told them about a brand-new green technology that charges in less than five minutes! It lasts hundreds of miles longer, is cheaper than batteries and can charge forever. And best of all, the tiny little-known stock behind it trades for only a few bucks.
Click here for the full story.
Sponsored
Is Alibaba Stock Price Forecast To Rise?
The Alibaba Group is China’s largest online shopping platform, operating a multi-engine business portfolio that includes retail marketplaces, logistical services, digital media and cloud computing. Revenues Keep Growing, But BABA Keeps Falling Alibaba’s financial figures for Q3 2021 were overwhelmingly positive. The company easily outperformed analyst’s expectations with an earnings per share of $3.41 (beating […]
Silver Profits: How to Make an Absolute Killing in the EV Boom
Silver investors are raking-in gains in 2021 as this critical metal surges on rising demand in the Green Energy Revolution. Look no further than silver's critical usage in EVs, solar, and 5G to know where the Smart-Money is headed. The best way to invest is in the small-cap silver space, and the next Wall St darling is this silver gem that's currently trading, undiscovered, at US$0.10 per share.
Sponsored
How Amazon AWS Got Started
How Amazon AWS Got Started: From 2006 to 2018, Dan Rose was a critical part of the Facebook (FB) executive team. As the Vice President of Partnerships, many credit Rose as the driving force behind Facebook’s growth into the social media giant it is today. However, Rose didn’t get his start with Mark Zuckerberg. Before […]
Tiny Biotech Creates $2 Trillion Drug
The Wall Street Journal reports new treatment is "transforming medicine."
Bill Gates writes that it could "help humanity."
Ark Investments think it could be a "$2 trillion market."
And one small company owns the patent on it.
This unknown biotech's stock is set to surge 46,751% >>>
Sponsored
Avalon GloboCare Stock Forecast
AVCO Stock Forecast: Not all biotech firms are created equal. Some companies specialize in drug discovery, or focus on a single aspect of a particular biomedical problem. These operations hope to array all their energies into solving one specific puzzle, and profit off of this by selling or licensing the results of their work at […]
New "Trojan Horse" Treatment Could Cost $2 Million
The New York Times reports new treatment "will change medicine."
Wall Street thinks it could be a $2 TRILLION market worldwide.
And one small company owns the patent on it.
This unknown biotech's stock is set to surge 46,751% >>>
Sponsored
View this email online if it doesn't display correctly. This newsletter is not financial advice. Please read our Disclaimer.
To unsubscribe from Financhill, click here.
Financhill is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of Financhill are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.
The sender of this email makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity's compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.
The content on any of Financhill websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The Financhill.com educational training program and software services are provided to improve financial understanding.
The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.
Past performance is no guarantee of future performance. This product is for educational purposes only. Practical application of the products herein are at your own risk and Financhill.com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Any trades shown are hypothetical example and do not represent actual trades. Actual results may differ. Nothing here in constitutes a recommendation respecting the particular security illustrated.
No comments:
Post a Comment